Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Capmatinib · Tabrecta, INC-280

Small molecule · Inhibitor of MET proto-oncogene, receptor tyrosine kinase (c-Met, HGF receptor) (MET) · developed by Novartis Pharm

Approved FDA, May 2020
NVS Developer

What is Capmatinib?

Capmatinib is an orally bioavailable kinase inhibitor that selectively binds the MET receptor tyrosine kinase, including the exon 14-skipping variant, and blocks its phosphorylation and downstream signaling. It is studied in non-small cell lung cancer driven by MET alterations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tabrecta, INC-280, INCB-28060
Drug type
Small molecule
Targets
MET proto-oncogene, receptor tyrosine kinase (c-Met, HGF receptor) (MET)
Mechanism
Inhibitor of MET proto-oncogene, receptor tyrosine kinase (c-Met, HGF receptor) (MET)
Pathways
MET signaling, MET phosphorylation and downstream signaling, cell proliferation and survival
Therapy area
Oncology
Developer
Novartis Pharm (NVS)
FDA status
Approved as Tabrecta (May 6, 2020), NDA213591 · FDA label
UNII
TY34L4F9OZ

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

EGFR-mutant Non-small Cell Lung Cancer

Other drugs acting on MET

More from Novartis Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Capmatinib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.